A Chat with Anat

"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer Consumer Care AG and produced by ApotheCom. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.

A Chat with Anat is a science podcast hosted by ApotheCom, with 27 episodes on record and a Required Pod Score of 80.

ApotheCom hosts A Chat with Anat, a science show with 27 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  A Chat with Anat

  Genetic therapy: What does the future hold and how can we be ready?

  Sep 29, 202622 min

  In this episode, I am joined by my fellow Vision Academy member Dr Cynthia Qian, Associate Professor of Clinical Ophthalmology at the University of Montreal, Montreal, Canada. Join us as we explore genetic therapies as emerging therapeutic approaches in ophthalmology. We provide a background and history of genetic therapies in ophthalmology and discuss current approaches and landscape, including ongoing trials and practical challenges. Finally, we dive into how healthcare systems, clinicians, and patients can all be prepared and supported as genetic therapies enter clinical practice. To learn more about genetic therapies and optogenetics, read the papers on genetic therapy updates and optogenetics for retinal diseases , co-authored by Cynthia. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, AbbVie, Astellas, Bayer, Boehringer Ingelheim, EyePoint Pharmaceuticals, Notal Vision, Ocular Therapeutix, Oculis, Ocuphire, Revenio, and Roche. Dr Cynthia Qian Consultant: AbbVie, Amgen, Apellis, Astellas, Bayer, Novartis, and Roche. Honoraria: AbbVie, Bayer, and Roche. Travel support: AbbVie, Bayer, and Roche. Advisory board member: Novartis. September 2026 | PP-PF-OPHT-ALL-0321-1 Further information on topics discussed in this podcast: AAO. Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations. 2022. Banadaki HD, Garanto A, Collin RWJ. Mol Aspects Med . 2025;106:101416. CELESTE. ClinicalTrials.gov: NCT07161544. Chan YK, et al. Transl Vis Sci Technol . 2021;10(4):3. Chen KY, et al. Drugs . 2025;85:1585–1608. de Oliveira Figueiredo EC, Bucolo C, Eandi CM . Curr Opin Ophthalmol . 2024;78:102484. Drag S, Dotiwala F, Upadhyay AK. Invest Ophthalmol Vis Sci . 2023;64:39. ENVISION. ClinicalTrials.gov: NCT06460844. Goldin MR, et al. Ophthalmic Genet . 2026;1–7. Hassan MSA-R, Zhong C, Hassan F, Li SK. Pharmaceutics . 2025;17:1326. HYPERION. ClinicalTrials.gov: NCT06891443. Irigoyen C, et al. J Clin Med . 2022;11:4717. Kim TH, et al. Gene Ther . 2026;33(4):383–397. Kohn DB, et al. Gene Ther . 2023;30:738–746. Krajewska JB, Waszczykowska A. J Appl Genet . 2026;67:325–337. Kulbay M, et al. J Clin Med . 2024;13:4224. Lu M, Milad D, Qian CX. Can Eye Care Today . 2024;3:4–11. LUNA. ClinicalTrials.gov: NCT06627179. Ma Y, Shen Y. Front Immunol . 2025;16:1664968. Maurya R, et al. Exp Eye Res . 2024;245:109983. RANZCO. Guidelines for the Assessment and Management of Patients with Inherited Retinal Diseases (IRD). 2020. RetNet. Retinal Information Network. https://retnet.org/summaries#a-genes. Wang D, Stevens G, Flotte TR. Mol Ther . 2025;33(5):1889–1902. This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

  ListenShow Notes
• 

  A Chat with Anat

  GLP-1 receptor agonists and vision health: What ophthalmologists should know

  Aug 31, 202616 min

  In this episode, I am joined by my fellow Barometer Program and Vision Academy member Professor Prof. Francisco J. Rodríguez, Chair at the National Ophthalmological Foundation and Chairman of the Department of Ophthalmology at the University of Rosario in Bogota, Colombia. Join us as we explore the growing evidence surrounding the use of glucagon-like peptide-1 (GLP-1) receptor agonists and their implications in ophthalmology. We discuss the latest preclinical and clinical data on GLP-1s in retinal disease, including diabetic retinopathy and age-related macular degeneration, examine emerging ocular safety topics, and consider the potential public health implications of widespread GLP-1 receptor agonist use. Finally, we discuss the role of ophthalmologists in monitoring patients and shaping future research in this rapidly evolving field. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT; AbbVie; Astellas; Bayer; Boehringer Ingelheim; EyePoint Pharmaceuticals; Notal Vision; Ocular Therapeutix; Oculis; Ocuphire; Revenio; and Roche Professor Francisco J. Rodríguez Consultant: Bayer, Novartis, and Roche; Speaker: Bayer, Novartis, and Roche; Research funding: Novartis August 2026 | PP-PF-OPHT-ALL-0320-1 Further information on topics discussed in this podcast: Ahuja A, et al. JAMA Ophthalmol. 2025;143:999–1003. Albanese GM. et al. Diabetology . 2025;6:117. Allan K. et al. Ophthalmol . 2025;132:748–57. Bain, SC. Diabetes & Primary Care . 23:103–4. Celletti F, et al. JAMA . 2026;335:434–38. FDA. Ozempic® (semaglutide) Prescribing Information. 2025, Luo Y, et al. BMC Ophthalmol. 2026;26:12. Pillai P, Modarressi T. Am Col Cardiol. 2024. Shor R, et al. JAMA Ophthalmol. 2025;143:587–94. Talebi R, et al. Retina . 2025;45:1663–71. Vilsbøll T, et al. Diabetes Obes Metab. 2018;20:889–97. Wołos-Kłosowicz K, et al. J Clin Med . 2022;11:6183. This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

  ListenShow Notes
• 

  A Chat with Anat

  Oculomics: From insight to practice

  Jul 6, 202626 min

  In this special episode filmed in Hong Kong at the 2026 Joint Vision Academy Steering Committee and Barometer Leadership Coalition meeting, I am joined by Professor Tien Yin Wong, Vice Provost and Chair Professor at the University of Tsinghua, Beijing, China, and previous Chairman of the Singapore Eye Research Institute, Singapore. Join us as we explore the concept of oculomics, including history of the field and its clinical implications. We dive into the recent interest in oculomics, its potential in enabling early detection of various systemic diseases, and how it may be employed by healthcare professionals to provide more personalized and accessible patient care. Finally, we discuss what challenges remain in integrating oculomics into clinical practice. To learn more about oculomics, read the paper on current concept and evidence of oculomics , co-authored by Tien. To find out more about the impact of AI on screening, diagnosis, and management of retinal disease, read the Vision Academy Consensus and publication . For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant Professor Tien Yin Wong Consultant: Aldropika Therapeutics, Bayer, Boehringer-Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio/Astellas Pharma, Novartis, Oxurion, Plano, Roche, Sanofi, Shanghai Henlius, and Zhaoke Pharmaceutical; and holds patents for and is the co-founder: EyRiS and Visre. June 2026 | PP-PF-OPHT-ALL-0303-1 This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  ListenShow Notes
• 

  A Chat with Anat

  Oculomics: From insight to practice

  Jul 6, 202626 minS0

  <p>In this special episode filmed in Hong Kong at the 2026 Joint Vision Academy Steering Committee and Barometer Leadership Coalition meeting, I am joined by Professor Tien Yin Wong, Vice Provost and Chair Professor at the University of Tsinghua, Beijing, China, and previous Chairman of the Singapore Eye Research Institute, Singapore.</p><p>Join us as we explore the concept of oculomics, including history of the field and its clinical implications. We dive into the recent interest in oculomics, its potential in enabling early detection of various systemic diseases, and how it may be employed by healthcare professionals to provide...

  ListenShow Notes
• 

  Episode #25

  Early signals and global stories from the HCP Barometer Survey

  Jun 12, 202637 minS0

  <p>In this special episode filmed at the 2026 Joint Vision Academy Steering Committee and Barometer Leadership Coalition meeting in Hong Kong, I am joined by Prof. David Wong, Professor at the University of Toronto and Ophthalmologist-in-Chief at St. Michael's Hospital in Canada.</p><p>Tune in as we discuss the interim findings from the HCP Barometer Survey – the first comprehensive and holistic analysis to explore healthcare professional (HCP) well-being in ophthalmology. We dive into the complexities of HCP well-being, including professional fulfilment, burnout, clinic capacity and coping strategies, and mental well-being. Finally, we delve into the roles and responsibilities of he...

  ListenShow Notes

Recent guests on A Chat with Anat. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.